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OBJECTIVE — ThisstudyprovidesnationallyrepresentativeestimatesfortheU.S.ofmedical
expenditures associated with diabetes by years since initial diagnosis.
RESEARCH DESIGN AND METHODS — Expenditures are estimated using cross-
sectional regression analysis on the 2000–2004 Medical Expenditure Panel Survey linked to the
1998–2003NationalHealthInterviewSurvey(n46,203).Theprimaryvariablesofinterestare
an indicator for self-reported diabetes and the years since diabetes diagnosis.
RESULTS — Under the base speciﬁcation, a 50-year-old person just diagnosed with diabetes
has medical expenditures that are 4,174 USD higher than an identical person without diabetes.
On average, each additional year with diabetes increases annual medical expenditures by $158
(standard error  $38) above and beyond increases in medical expenditures due to aging.
Conditional on diabetes complications, each additional year with diabetes increases annual
medical expenditures by $75 (standard error  $55). Diabetes increases medical expenditures
at any age, and the cumulative effect grows over time.
CONCLUSIONS — The results show the expected trajectory of medical expenditures after
diagnosis of diabetes, highlighting the beneﬁts of prevention and control as well as informing
cost-effectiveness models of diabetes interventions.
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D
iabetesanditscomplicationscanbe
costly to treat for individuals and
society (1). To study the cost-
effectiveness of interventions designed to
prevent and treat diabetes, an estimate of
thelifetimecostsforindividualswithdiabe-
tes, often under “usual” or “standard” care,
is required. However, few studies have de-
scribed how the cost of diabetes changes
over time after diagnosis of diabetes.
Themajorityofsuchstudiesreliedon
health insurance databases (2–4). The
typical pattern is a surge in spending ini-
tially after diagnosis of diabetes, then a
leveling out, and then a rise toward the
end of life. One caveat of these studies is
thattheymaynotgeneralizetootherpop-
ulations. Other studies have been based
on populations from Canada (5) and the
U.K. (6). To our knowledge, a nationally
representative estimate of the medical
costs of diabetes by time since diagnosis
does not exist for the U.S.
This study provides nationally rep-
resentative estimates of medical expen-
ditures associated with diabetes by
years since initial diagnosis. We link
adults in the National Health Interview
Survey (NHIS), which includes data on
the age of ﬁrst diagnosis for individuals
who report having diabetes, to their
medicalexpendituredataintheMedical
Expenditure Panel Survey (MEPS). The
resulting cross-section includes adults
who have had diabetes for various
lengths of time. We use regression
methods to estimate the medical expen-
diture proﬁle of individuals with diabe-
tes by the number of years with
diabetes. The results show the expected
trajectory of medical expenditures after
diagnosis of diabetes, highlighting the
beneﬁts of prevention and control as
well as informing cost-effectiveness
models of diabetes interventions.
RESEARCH DESIGN AND
METHODS
Data
The primary sample for the analysis is
drawn from the 2000–2004 MEPS. The
MEPSisanationallyrepresentativesurvey
of the civilian noninstitutionalized popu-
lation administered by the Agency for
Healthcare Research and Quality. The
MEPSprovidesdataonparticipants’med-
ical expenditures, medical conditions,
and demographic characteristics (e.g.,
race/ethnicity, sex, and education).
The MEPS includes information on
whether participants have ever been told
theyhavediabetesbutdoesnotreportthe
age of onset of diabetes. To ﬁnd the age of
onset for individuals with diabetes, we
link participants in MEPS to their survey
responses in the 1998–2003 NHIS adult
ﬁles. The MEPS sample is drawn from a
subset of the households that participate
in the NHIS. The subsample of NHIS par-
ticipants chosen for inclusion in MEPS
enter the MEPS framework in the next
year and remain for 2 years. For example,
a participant in the 2000 NHIS selected
for the MEPS sample will appear in the
2001 and 2002 MEPS.
The estimation sample is restricted to
participants in both surveys with infor-
mationaboutdiabetesprevalenceandage
of onset (n  3,790 with diabetes, n 
42,413 without diabetes). The MEPS is
the primary source for diabetes preva-
lence;weuseMEPSvalueswhenthereare
discrepancies between MEPS and NHIS
(e.g.,fornewcasesofdiabetesthatinitiate
betweenthesurveys).Thevastmajorityof
self-reports for diabetes agree between
MEPS and NHIS (98% of sample). We
code participants who report being told
they have diabetes in the MEPS but not in
the NHIS as new cases of diabetes with
duration 2 years, the maximum time
betweenthetwosurveys.Thesenewcases
are 1.7% of the sample. Using NHIS
data, the Centers for Disease Control and
Prevention (CDC) (7) report the annual
incidence of diabetes in 2004 was 7.2 per
1,000population(0.72%).Thus,a2-year
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linked sample is slightly higher than that
found in the NHIS alone (1.44%). If we
restrictthesampletoages18–79years,as
in the CDC report, the 2-year incidence
rate is 1.65%; the remainder of the differ-
ence is likely due to methodological dif-
ference (e.g., CDC used 3-year moving
averages) or to reporting error.
Neither survey distinguishes between
type 1 and type 2 diabetes. In separate
analyses, to try and isolate individuals
with type 2 diabetes, we drop the sample
of individuals whose diabetes began be-
foreage21years(n216)andbeforeage
25 years (n  285).
Statistical models
The main goal is to estimate how medical
expenditures change over time with diabe-
tes. We include participants without diabe-
tes to help identify the effects of aging on
medical expenditures separate from the ef-
fects of additional years with diabetes.
We use regression analysis to control
for observable differences among partici-
pants and between individuals with and
without diabetes that are likely to affect
medical expenditures. Because annual
medical expenditures are positively
skewed, we model annual medical expen-
ditures using a generalized linear model
withlog-linkandgammavariancefunction.
Wealsoreportsensitivityteststoalternative
models including ordinary least squares
and two-part models. Two-part models use
a logit to model the probability of any ex-
penditures and a separate regression to
model expected medical expenditures con-
ditional on having any expenditures.
The regression includes an indicator
for having diabetes; that indicator inter-
acted with the duration of diabetes and
the duration of diabetes squared, age, age
squared, and interaction of the diabetes
indicator with age and age squared. The
duration variables are of primary interest.
Ageandagesquaredcontrolfortheeffects
of age on annual medical expenditures
common to individuals with and without
diabetes. The interaction of the diabetes
indicator with age and age squared pro-
vide a way to test for differences in the
effectofagebetweenindividualswithand
without diabetes.
Diabetesincreasestherisksforseveral
medicalconditionsthatdevelopovertime
(8). We estimate the effect of diabetes du-
ration on annual medical expenditures
two ways: unconditional on diabetes
complications and conditional on diabe-
tes complications. The latter speciﬁcation
includesindicatorsforself-reportedprev-
alence of heart disease, stroke, congestive
heart failure, hypertension, high choles-
terol, and renal failure.
All regressionsalsoincludeasindepen-
dent variables the following demographic
variables: sex, race/ethnicity (white [omit-
ted], black, Hispanic, Asian, other), educa-
tion (education missing, less than high
school,highschooldiploma,collegedegree
[omitted], graduate degree, other degree),
family income (100%, 100–199%, 200–
399% [omitted], 400% of the poverty
line)(9),primarysourceofhealthinsurance
(Medicaid, Medicare, private insurance
[omitted], other public insurance, unin-
sured), and census region and study year
indicators.
Usingpredictionsfromtheregression
models, we report the effects of diabetes
duration on annual medical expenditures
in two ways. First, we report the incre-
mental effect of 1 additional year with di-
abetes, holding all other variables
constant. We report the mean of the pre-
dicted incremental effects among partici-
pants with diabetes and bootstrapped
standard errors from 500 replications of
the model. Second, we graph the average
incremental cost of diabetes by duration
(years with diabetes) for the average per-
son with diabetes. The average incremen-
tal cost is the difference in predicted
expenditures between the average person
with diabetes and an identical person, in-
cluding comorbidities, without diabetes.
Table 1—Summary statistics by diabetes status: 2000–2004 MEPS merged to 1998–2003
NHIS
With diabetes
(n  3,790)
Without diabetes
(n  42,413)
Mean SD Mean SD
Annual medical expenditures (USD) 10,913 19,886 3,630 8,735
Age of diabetes onset 50.40 18.27 — —
Years with diabetes 10.96 13.19 — —
Age 61.37 15.41 46.71 16.60
n Weighted % n Weighted %
Female 2,291 55.4 24,618 55.0
White 2,050 67.4 26,829 75.0
Black 818 16.7 5,929 11.0
Hispanic 765 11.4 7,773 10.0
Asian 66 2.2 1,210 3.0
Other race 91 2.3 672 1.0
100% poverty level 886 16.0 6,762 11.0
100–199% poverty level 1,016 25.5 8,662 17.0
200–399% poverty level 1,025 29.3 12,677 31.0
400% poverty level 863 29.2 14,312 41.0
Missing education 14 0.3 105 0.2
Less than high school 1,324 27.5 8,458 14.0
High school diploma 1,776 49.9 21,540 51.0
College degree 348 11.8 6,230 18.0
Graduate degree 141 4.7 3,199 9.0
Other degree 187 5.7 2,881 7.0
Medicaid 377 7.0 3,555 5.5
Medicare 1,861 48.8 7,897 18.2
Private insurance 1,086 33.1 23,178 61.1
Other public insurance 203 5.7 1,413 3.2
Uninsured 263 5.4 6,370 12.0
Heart disease 933 26.0 3,057 7.0
Stroke 174 5.0 417 1.0
Congestive heart failure 175 5.0 215 0.5
Hypertension 2,195 57.0 7,665 17.0
High cholesterol 1,234 34.0 3,858 9.0
Renal failure 74 2.0 74 0.1
MEPS survey weights are used to make the means, SDs, and frequencies (%) nationally representative of the
period 2000–2004.
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all analyses to make the results nationally
representative of the period of 2000–
2004. All expenditures have been con-
verted to 2005 USD using the Medical
Care Consumer Price Index (10).
RESULTS— We identiﬁed 3,790
adultsself-reportedtohavebeentoldthey
have diabetes—8.2% of the estimation
sample(Table1).Theaverageageofonset
for these adults is 50 years. The average
age at which we observe their annual
medical expenditures is 61 years.
Whereas the mean duration for individu-
als with diabetes in our sample is almost
11 years, 40% of the diabetes sample has
durationof5years;25%hasdurationof
2 years. Unadjusted mean annual med-
ical expenditures for adults with diabetes
are about $7,000 higher than for adults
without diabetes. However, adults with
diabetes are different from adults without
diabetes in a number of observable ways.
Individuals with diabetes are older and
more likely to be of minority ethnicity, be
poor,belesseducated,andhavediabetes-
related comorbidities.
Controlling for demographic differ-
ences between individuals with and with-
out diabetes, individuals with diabetes
have annual medical expenditures about
239%higherthanindividualswithoutdi-
abetes (Table 2, base speciﬁcation). An-
nual medical expenditures increase at a
decreasing rate as the time with diabetes
increases. Aging also increases medical
expenditures at a decreasing rate. The co-
efﬁcient for the interaction between dia-
betes and age is negative, indicating that
the effect of aging on medical expendi-
tures is smaller for individuals with dia-
betes than for individuals without
diabetes.
Conditional on diabetes-related co-
morbidities,annualmedicalexpenditures
are still higher among those with diabetes
(Table 2, add comorbidities). Annual
medical expenditures increase at a de-
creasing rate as the time with diabetes in-
creases. However, the magnitude of the
coefﬁcients for diabetes and diabetes du-
ration are smaller than in the model that
does not control for comorbidities.
An additional year with diabetes,
holding demographic variables constant,
increases average annual medical expen-
ditures by $158 (standard error  $38;
Table3).Theaverageincrementaleffectis
unaffected by choice of alternative func-
tional forms. Ordinary least squares, a
two-part model using generalized linear
model with log-link and gamma variance
in the second part, and a two-part model
usingordinaryleastsquaresonlogexpen-
ditures with a heteroscedastic smearing
retransformation(11)allyieldaveragein-
cremental effects of an additional year
with diabetes near $158. When we re-
strictthesampletopeoplewhosediabetes
beganatage21yearsorlaterandatage25
years or later, the average incremental ef-
fect of an additional year with diabetes is
$184 and $173, respectively (results are
available upon request).
Conditional on diabetes-related co-
morbidities, an additional year with dia-
betes increases average annual medical
expenditures by $75 (standard error
$55). The average incremental effect var-
ies more with choice of functional form
when comorbidities are included, but all
of the slope estimates are smaller when
compared with a speciﬁcation uncondi-
tional on comorbidities.
Figure1showstheaverageincremen-
tal cost of diabetes as a function of the
number of years with diabetes. The incre-
mental costs are plotted separately for a
personatage50yearsandatage65years,
Table 2—Regression models of annual medical expenditures as a function of time with dia-
betes: generalized linear model with log-link and gamma variance
Base speciﬁcation Adjusted for comorbidities
Coefﬁcient SE Coefﬁcient SE
Diabetes 2.387 * 0.736 2.185 * 0.640
Years with diabetes 0.024 * 0.006 0.011 * 0.005
Years with diabetes squared 0.0004 * 0.0001 0.0002 * 0.0001
Age 0.060 * 0.005 0.058 * 0.005
Age squared 0.0004 * 0.00005 0.0004 * 0.00005
Diabetes-age interaction 0.050 * 0.024 0.053 * 0.021
Diabetes-age squared interaction 0.0003 0.0002 0.0004 * 0.0002
Female 0.304 * 0.027 0.352 * 0.028
Black 0.302 * 0.038 0.310 * 0.040
Hispanic 0.400 * 0.041 0.372 * 0.041
Asian 0.523 * 0.087 0.474 * 0.087
Other race 0.057 0.075 0.086 0.075
100% poverty level 0.217 * 0.049 0.211 * 0.051
100–199% poverty level 0.035 0.041 0.042 0.043
400% poverty level 0.023 0.031 0.047 0.032
Missing education 0.335 0.200 0.361 0.203
Less than high school 0.262 * 0.050 0.284 * 0.051
High school 0.112 * 0.041 0.114 * 0.040
Graduate degree 0.016 0.057 0.011 0.053
Other degree 0.049 0.057 0.046 0.056
Medicaid 0.699 * 0.062 0.635 * 0.065
Medicare 0.556 * 0.047 0.486 * 0.050
Other public insurance 0.378 * 0.060 0.319 * 0.057
Uninsured 0.850 * 0.062 0.817 * 0.067
Midwest 0.078 * 0.038 0.076 * 0.037
South 0.045 0.039 0.015 0.038
West 0.036 0.040 0.032 0.037
Year 2000 0.151 * 0.046 0.116 * 0.046
Year 2001 0.065 0.042 0.024 0.044
Year 2002 0.083 * 0.034 0.054 0.034
Year 2003 0.015 0.037 0.005 0.035
Heart disease — — 0.748 * 0.042
Stroke — — 0.721 * 0.070
Congestive heart failure — — 0.709 * 0.100
Hypertension — — 0.345 * 0.029
High Cholesterol — — 0.185 * 0.030
Renal Failure — — 1.414 * 0.119
Constant 6.427 * 0.119 6.114 * 0.121
Sample size 46,203 46,203
2000–2004 MEPS merged to 1998–2003 NHIS. *Signiﬁcance at the 95% CI.
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cation and for the speciﬁcation that adds
comorbidities (Table 2). Under the base
speciﬁcation, a 50-year-old person just
diagnosed with diabetes has medical ex-
pendituresthatare$4,174higherthanan
identical person without diabetes. A 50-
year-old person who has had diabetes for
10 years has medical expenditures that
are $6,054 higher than an identical per-
son without diabetes. Controlling for co-
morbidities lowers the incremental cost of
diabetes at age 50 years and at age 65 years
and also lowers the slope with respect to
duration at both ages, which is consistent
with the results reported in Table 3. For ex-
ample, a 65-year-old person just diagnosed
with diabetes has medical expenditures
$2,361higherthananidenticalpersonwith
the same comorbidities but without diabe-
tes. The incremental cost of diabetes is
$3,103atage65yearsforapersonwhohas
had diabetes for 10 years.
CONCLUSIONS— This study is the
ﬁrst to provide nationally representative es-
timates of how annual medical expendi-
tures increase with the length of time with
diabetes. On average, each additional year
with diabetes increases annual medical ex-
penditures by $158. This is in addition to
baseline increases in medical expenditures
with age. Thus, not only does diabetes in-
crease medical expenditures at any age, but
the effect grows over time.
The increase in diabetes-related medi-
cal expenditures over time is likely due to
two causes. First, diabetes increases the
risks for several medical conditions that de-
velopovertime.Whenseveralofthesecon-
ditions are included in the model, the
estimate of the effect of an additional year
with diabetes on annual medical expendi-
tures falls to $75, a 53% reduction. Thus, a
higher prevalence of these conditions
among individuals with diabetes explains
the majority of the effect of diabetes dura-
tion. However, even conditional on diabe-
tes complications, diabetes duration has a
signiﬁcant effect on annual medical expen-
ditures. The remaining signiﬁcance of dia-
betes duration could be the result of
incomplete control for complications (e.g.,
microalbuminuria, retinopathy, and neu-
ropathyarenotincluded).Thisresultdiffers
from two previous studies that found that
controlling for diabetes complications, dia-
betes duration (4), and age among individ-
uals with diabetes (12) are not signiﬁcant
predictors of medical expenditures.
Second, management of blood glu-
cose and insulin levels becomes more dif-
ﬁcult over time. Results from the UK
Prospective Diabetes Study indicate that
mostpatientswillneedmultipletherapies
to attain target control rates in the long
term (13). This leads to increases in man-
agement costs for diabetes as diabetes du-
ration increases.
All of these results suggest that while
much of the increased cost of diabetes over
time could be avoided by prevention of di-
abetes-related complications, control of di-
abetes itself generates costs. When the
analyses above were repeated using pre-
scription drug expenditures as the depen-
dent variable, another year with diabetes
increases prescription drug expenditures
by $56 per person (results available upon
request). Adjusting for comorbidities, this
effect remains $52 per person. Thus, con-
trollingforcomorbidities,alargepartofthe
increase in diabetes costs over time is the
result of higher prescription drug expendi-
tures, an essential component to diabetes
control and management.
Theresultsofthisstudyaresubjectto
several limitations. Medical conditions,
including diabetes, are self-reported. It is
notpossibletodistinguishbetweentype1
and type 2 diabetes. When individuals
whose diabetes began before age 21 years
(a proxy for type 1 diabetes) are dropped
from the sample, the average incremental
effectofanadditionalyearwithdiabetesis
slightly higher, but not statistically signif-
icantly different from the full sample. The
datausedinthisstudyarecross-sectional,
not longitudinal. Rather than following
individuals for several years after onset of
diabetes, the data contain a cross-section
of individuals that have had diabetes for
different lengths of time. This might ex-
plainthefactthatwedonotﬁndtheinitial
spike in medical expenditures around the
time of diagnosis that has been observed
in longitudinal studies. The data are also
Figure 1—Average incremental cost of diabetes: difference in expenditures with and without
diabetes.
Table 3—Average incremental effect of 1 additional year with diabetes among individuals
with diabetes (bootstrapped standard error)
Generalized linear
model (GLM)
Ordinary least
squares (OLS)
Two-part
model: GLM
Two-part
model: OLS
Base speciﬁcation 158 (38) 199 (45) 155 (36) 190 (25)
Adjusted for comorbidities 75 (55) 114 (58) 74 (52) 129 (40)
Results are expressed in 2005 USD. All models use the same variables as in Table 2. Both two-part models
estimatealogitfortheprobabilityofanymedicalexpenditures.Two-partmodel:GLMusesaGLMmodelon
non-zero expenditures. Two-part model: OLS uses OLS on log (non-zero) expenditures with a heterosce-
dastic retransformation.
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of the bias will depend on the length of
time spent with diabetes and the medical
expenditure patterns of those who died
and are not included in the survey.
To our knowledge, these are the ﬁrst
nationallyrepresentativeestimatesforthe
U.S. of the expected trajectory of medical
expenditures after diagnosis of diabetes.
They provide additional evidence high-
lighting the beneﬁts of diabetes preven-
tion and control. Delaying the
development of diabetes will delay the
steady rise in medical expenditures that
accompanies it.
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